查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
注射給藥的全球市場：按類型（設備/製劑）、治療目標（感染疾病/癌症）、使用模式（免疫）、給藥部位（皮膚/肌肉骨骼系統）、配銷通路、患者照護環境和地區 -預測（~2029）
市場調查報告書
商品編碼
1488766

注射給藥的全球市場：按類型（設備/製劑）、治療目標（感染疾病/癌症）、使用模式（免疫）、給藥部位（皮膚/肌肉骨骼系統）、配銷通路、患者照護環境和地區 -預測（~2029）

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious diseases,Cancer), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), Distribution Channel,Patient Care Setting, & Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 387 Pages | 訂單完成後即時交付

價格
簡介目錄

全球注射給藥市場規模預計將從2024年的7,545億美元成長到2029年的1,1,394億美元，預測期內複合年成長率為8.6%。

糖尿病、癌症、自體免疫疾病和心血管疾病等慢性病的盛行率不斷增加，需要開發更有效、更量身訂做的藥物傳遞策略。注射藥物輸送系統可實現精確劑量和客製化輸送，以改善治療效果。

調查範圍
調查年份 2021-2029
基準年 2023年
預測期 2024-2029
單元 金額（美元）
部分 按類型、包裝、目標處理、使用方式、給藥地點、分銷管道、使用環境
目標區域 北美、歐洲、亞太地區、中東和非洲

單株抗體、胜肽和核酸療法等生技藥品的使用不斷增加，增加了對注射遞送系統的需求。這些大化合物通常生物有效性較差，需要腸胃外給藥才能有效遞送。

製劑產業在預測期內將佔據最大佔有率：

注射劑用於治療多種疾病，包括腫瘤、糖尿病、自體免疫疾病、心血管疾病、感染疾病和神經系統疾病。注射劑適應性強，可以傳遞多種藥物，包括小分子、生技藥品、胜肽和疫苗，這是廣泛使用的原因之一。注射劑與各種藥物輸送裝置相容，包括預填充式注射器、管瓶、安瓿、藥筒、自動注射器、筆和輸液幫浦。這些輸送系統正在推動對注射劑的需求，因為它們易於使用、精確劑量和患者便利。生技藥品和單株抗體在醫學中的使用不斷增加，推動了對注射劑的需求。生技藥品可能需要腸胃外給藥，因為它們的分子尺寸大、對酵素分解敏感且生物有效性低。注射製劑允許生技藥品皮下或肌肉內給藥，從而實現最佳的遞送和治療效果。

以包裝來看，安瓿類別佔比最大：

安瓿是密封的玻璃容器，可有效阻擋污染、濕氣和空氣，並保持內部藥物的無菌和穩定性。安瓿的密封特性限制了微生物的生長和治療產品的劣化，降低了感染疾病風險並在使用前保持藥物的完整性。

以治療目標來看，預計在預測期內感染疾病將佔據最大佔有率：

注射藥物的施用對於治療多種傳染病至關重要，包括細菌、病毒、真菌和寄生蟲感染。許多抗生素、抗病毒治療、抗真菌藥物和抗寄生蟲藥物均透過注射給藥，以在血液和目標組織中實現快速有效的藥物濃度。注射藥物廣泛用於治療結核病和愛滋病毒/愛滋病等慢性感染疾病。為了有效靶向結核菌並防止抗藥性，結核病治療通常採用口服抗生素和利福平、異煙肼、鏈黴素等注射劑的組合。同樣，愛滋病毒/愛滋病治療方法使用注射型抗逆轉錄病毒藥物來抑制病毒複製並防止疾病進展。

從地區來看，亞太地區預計在預測期內複合年成長率最高：

隨著人口老化，包括日本、韓國和中國在內的亞太國家正經歷人口變化。老年人慢性病盛行率高，醫療保健需求複雜，增加了對治療糖尿病、心血管疾病和癌症等疾病的注射藥物的需求。

該報告調查了全球注射給藥市場，並提供了市場概況、市場影響因素和市場機會分析、技術和專利趨勢、監管和報銷環境、未滿足的需求、市場規模趨勢和預測以及各種其他資訊。按類別/地區/主要國家、競爭格局和主要企業概況。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 任務
  • 價值鏈分析
  • 供應鏈分析
  • 關稅和監管狀況
  • 關稅和監管分析
  • 監管機構、政府機構和其他組織
  • 生態系分析
  • 技術分析
  • 專利分析
  • 重大會議及活動
  • 影響客戶業務的趨勢/干擾
  • 波特五力分析
  • 主要相關利益者和採購標準
  • 贖回場景
  • 藥物輸送市場未滿足的需求
  • 投資場景

第6章注射給藥市場：依類型

  • 裝置
    • 傳統注射器
    • 自注射器
  • 公式
    • 常規注射
    • 新注射
    • 長效注射劑

第7章注射給藥市場：依治療標靶

  • 自體免疫疾病
    • 類風濕性關節炎
    • 多發性硬化症
    • 克隆氏症
    • 乾癬
    • 其他
  • 荷爾蒙失調
    • 糖尿病
    • 貧血
    • 生殖健康相關疾病
    • 抗血栓/溶栓
    • 骨質疏鬆症
    • 生長激素缺乏症
  • 罕見疾病
  • 癌症
  • 感染疾病
  • 其他
    • 疼痛管理
    • 過敏
    • 美容治療
    • C型肝炎
    • 血友病

第8章注射給藥市場：依包裝分類

  • 安瓿
  • 管瓶
  • 墨水匣
  • 瓶子

第9章注射給藥市場：依使用模式分類

  • 治療護理
  • 疫苗接種
  • 其他

第10章注射給藥市場：依給藥地點分類

  • 經皮
  • 循環系統/肌肉骨骼
  • 器官
  • 中樞神經系統

第11章注射給藥市場：依分銷管道分類

  • 醫院
  • 零售藥房

第12章注射給藥市場：患者照護環境分類

  • 醫院/診所
  • 居家照護
  • 其他

第13章注射給藥市場：按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第14章競爭格局

  • 概述
  • 主要企業/主要企業策略
  • 收益分析
  • 市場佔有率分析
  • 公司評估矩陣：注射製劑製造商
  • 公司評估矩陣：注射輸送設備製造商
  • 企業價值評估及財務指標
  • 產品/品牌比較
  • 競爭場景

第15章 公司簡介

  • 注射給藥製劑製造商
    • BECTON, DICKINSON AND COMPANY
    • PFIZER, INC.
    • JOHNSON & JOHNSON SERVICES, INC.
    • SANDOZ GROUP AG
    • MERCK& CO., INC.
    • GLAXOSMITHKLINE PLC
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • ELI LILLY AND COMPANY
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • BAXTER INTERNATIONAL, INC.
    • GERRESHEIMER AG
    • SCHOTT PHARMA
  • 注射輸送裝置製造商
    • TERUMO CORPORATION
    • ANTARES PHARMA, INC.
    • B. BRAUN MELSUNGEN AG
    • SMITHS MEDICAL
    • FRESENIUS KABI AG

第16章附錄

簡介目錄
Product Code: MD 3680

The global Injectable drug delivery market is projected to reach USD 1139.4 billion by 2029 from USD 754.5 billion in 2024, at a CAGR of 8.6% from 2024 to 2029. The increased prevalence of chronic diseases such as diabetes, cancer, autoimmune disorders, and cardiovascular disease needs the development of more effective and tailored medication delivery strategies. Injectable drug delivery systems enable precision dosing and tailored distribution, which improves treatment outcomes.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsType, By Formulation packaging, Therapeutic application, Usage Pattern, By site of administration, distribution channel and facility of Use
Regions coveredNorth America, Europe, APAC, LATAM, MEA

The growing usage of biologics, such as monoclonal antibodies, peptides, and nucleic acid-based therapies, has increased the need for injectable delivery systems. These big compounds frequently have low oral bioavailability and require parenteral treatment for efficient distribution.

"The Formulations segmented accounted for the largest share during the forecast period."

Injectable medication formulations are utilized for a variety of therapeutic purposes, including oncology, diabetes, autoimmune illnesses, cardiovascular disease, infectious diseases, and neurological disorders. The adaptability of injectable formulations enables the delivery of a wide range of medications, including small molecules, biologics, peptides, and vaccines, which contributes to their widespread use. Injectable formulations work with a variety of drug delivery devices, such as prefilled syringes, vials, ampoules, cartridges, autoinjectors, pen injectors, and infusion pumps. These delivery systems increase market demand for injectable drug formulations by providing ease of use, accurate dosing, precise administration, and patient convenience. The growing usage of biologic pharmaceuticals and monoclonal antibodies in healthcare has driven up demand for injectable medication formulations. Biologics sometimes require parenteral delivery due to their high molecular size, vulnerability to enzymatic breakdown, and low oral bioavailability. Injectable formulations allow biologics to be administered subcutaneously or intramuscularly, resulting in optimal drug delivery and therapeutic efficacy.

"The ampoules segment accounts for the largest segment in formulation packaging segment."

Ampoules are hermetically sealed glass containers that provide an effective barrier to contamination, moisture, and air, maintaining the sterility and stability of the medication inside. The sealed form of ampoules inhibits microbial development and degradation of the therapeutic product, lowering the risk of infection and conserving the medication's integrity until usage.Glass ampoules provide good protection against light and air, which can damage and destabilize certain drugs over time. The opaque quality of glass limits light exposure, while the hermetic barrier prevents oxygen entrance, ensuring that light-sensitive and oxygen-sensitive medications retain their potency and efficacy.

"By Therapeutic application Infectious diseases accounted for the largest share during the forecast period."

Injectable drug administration is essential for treating a wide range of infectious disorders, including bacterial, viral, fungal, and parasitic infections. Many antibiotics, antiviral treatments, antifungal agents, and antiparasitic medications are given as injections to achieve quick and effective drug concentrations in the bloodstream and target tissues. Injectable drugs are widely used to treat chronic infectious disorders like tuberculosis (TB) and HIV/AIDS. To efficiently target the TB germs and prevent medication resistance, TB treatment frequently combines oral antibiotics with injectable treatments such as rifampin, isoniazid, and streptomycin. Similarly, injectable antiretroviral medications can be used in HIV/AIDS therapy regimens to reduce viral replication and prevent disease progression.

"APAC is estimated to register the highest CAGR during the forecast period."

The Injectable drug delivery market is divided into Five regions- North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The Asia Pacific is witnessed to have the highest CAGR during the forecast period.. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. Older persons have a higher prevalence of chronic diseases and complex healthcare needs, which drives the demand for injectable drugs for ailments like diabetes, cardiovascular disease, and cancer.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
  • By Designation: C-level (30%), Director-level (20%), and Others (50%)
  • By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW(16%)

List of Companies Profiled in the Report

    • Becton, Dickinson and Company (U.S.),
    • Pfizer Inc. (U.S.),
    • Teva Pharmaceuticals Industries Ltd. (Israel),
    • Eli Lilly and Company (U.S.),
    • Baxter International, Inc. (U.S.),
    • Sandoz (Germany),
    • Terumo (Japan),
    • Schott AG (Germany),
    • Gerresheimer (Germany),
    • Ypsomed (Switzerland),
    • Bespak (U.K.), and
    • B. Braun Melsungen (Germany).

Research Coverage

This report studies the Injectable drug delivery market based on type, formulation packaging, site of administration, route of administration, facility of use, distribution channels and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments to five major regions.

Reasons to Buy the Report

This report also includes.

  • Analysis of key drivers (increasing chronic diseases, increasing biologics, technological advancements) ,restraints (Infections associated with needle stick injuries), challenges(Other methods of Injectable drug delivery available in the market), opportunities (Increase in the demand of generic medicines and biosimilars) contributing the growth of the Injectable drug delivery market.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Injectable drug delivery market.
  • Market Development: Comprehensive information on the lucrative emerging markets by type, formulation packaging, by site of administration,facility of use and region.
  • Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the Injectable drug delivery market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Injectable drug delivery market..

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 MARKET SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 REGIONAL SEGMENTATION
    • FIGURE 1 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
    • FIGURE 6 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
    • 2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
    • FIGURE 7 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.2.3 APPROACH 3: TOP-DOWN APPROACH
    • FIGURE 8 TOP-DOWN APPROACH
    • 2.2.4 APPROACH 2: BOTTOM-UP APPROACH: SUPPLY-SIDE ANALYSIS
    • FIGURE 9 BOTTOM-UP APPROACH
    • 2.2.5 APPROACH 4: PRIMARY INTERVIEWS
  • 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ASSESSMENT
  • 2.5 STUDY ASSUMPTIONS
    • TABLE 1 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 2 RISK ASSESSMENT ANALYSIS
  • 2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
    • FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2024 VS. 2029 (USD BILLION)
    • FIGURE 13 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2024 VS. 2029 (USD BILLION)
    • FIGURE 14 GEOGRAPHIC SNAPSHOT OF INJECTABLE DRUG DELIVERY MARKET

4 PREMIUM INSIGHTS

  • 4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW
    • FIGURE 15 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • 4.2 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE AND COUNTRY (2023)
    • FIGURE 16 FORMULATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • 4.3 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
    • FIGURE 17 SELF-INJECTION DEVICES SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 MARKET DYNAMICS
    • FIGURE 19 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.1.1 DRIVERS
      • 5.1.1.1 Rising prevalence of chronic diseases
      • 5.1.1.2 Growing demand for self-injection devices
      • 5.1.1.3 Growth in biologics market
    • TABLE 3 INDICATIVE LIST OF BIOLOGICS APPROVED BY US FDA (2020)
      • 5.1.1.4 Technological advancements in injectable drug delivery products
    • 5.1.2 RESTRAINTS
      • 5.1.2.1 Infections associated with needlestick injuries
      • 5.1.2.2 Higher cost of development compared to conventional injections
    • 5.1.3 OPPORTUNITIES
      • 5.1.3.1 Increasing demand for biosimilars and generic injectables
        • 5.1.3.1.1 Biosimilars
        • 5.1.3.1.2 Generic injectables
      • 5.1.3.2 Contraceptive injectables
    • 5.1.4 CHALLENGES
      • 5.1.4.1 Alternative methods of drug delivery
  • 5.2 VALUE CHAIN ANALYSIS
    • 5.2.1 RESEARCH & DEVELOPMENT
    • 5.2.2 PROCUREMENT & PRODUCT DEVELOPMENT
    • 5.2.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES
    • FIGURE 20 INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
  • 5.3 SUPPLY CHAIN ANALYSIS
    • 5.3.1 PROMINENT COMPANIES
    • 5.3.2 SMALL & MEDIUM-SIZED COMPANIES
    • 5.3.3 END USERS
    • FIGURE 21 INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.4 TARIFF AND REGULATORY LANDSCAPE
    • 5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 4 REGULATORY SCENARIO, BY COUNTRY
  • 5.5 TARIFF AND REGULATORY ANALYSIS
    • 5.5.1 NORTH AMERICA
      • 5.5.1.1 US
      • 5.5.1.2 Canada
    • 5.5.2 EUROPE
    • 5.5.3 ASIA PACIFIC
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
    • 5.5.4 LATIN AMERICA
    • 5.5.5 MIDDLE EAST
  • 5.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 22 INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.3 ADJACENT TECHNOLOGIES
  • 5.9 PATENT ANALYSIS
    • FIGURE 23 PATENT ANALYSIS FOR INJECTABLE DRUG DELIVERY MARKET (JANUARY 2014-DECEMBER 2023)
  • 5.10 KEY CONFERENCES AND EVENTS, 2023-2024
    • TABLE 9 INJECTABLE DRUG DELIVERY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023-2024
  • 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 25 INJECTABLE DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • TABLE 10 INJECTABLE DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 THREAT OF NEW ENTRANTS
    • 5.12.2 THREAT OF SUBSTITUTES
    • 5.12.3 BARGAINING POWER OF SUPPLIERS
    • 5.12.4 BARGAINING POWER OF BUYERS
    • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 26 KEY STAKEHOLDERS IN BUYING PROCESS
    • TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%)
  • 5.14 REIMBURSEMENT SCENARIO
    • TABLE 12 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES
  • 5.15 UNMET NEEDS IN INJECTABLE DRUG DELIVERY MARKET
  • 5.16 INVESTMENT SCENARIO
    • FIGURE 27 NUMBER OF INVESTOR DEALS IN INJECTABLE DRUG DELIVERY MARKET, BY KEY PLAYER, 2019-2022
    • FIGURE 28 VALUE OF INVESTOR DEALS IN INJECTABLE DRUG DELIVERY MARKET, BY KEY PLAYER, 2019-2022 (USD MILLION)

6 INJECTABLE DRUG DELIVERY MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 13 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
  • 6.2 DEVICES
    • TABLE 14 INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 15 INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY REGION, 2021-2029 (USD BILLION)
    • 6.2.1 CONVENTIONAL INJECTION DEVICES
      • 6.2.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive market
    • TABLE 16 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.1.2 By material
    • TABLE 17 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2021-2029 (USD BILLION)
        • 6.2.1.2.1 Glass
    • TABLE 18 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.1.2.2 Plastic
    • TABLE 19 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.1.3 By product
    • TABLE 20 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2021-2029 (USD BILLION)
        • 6.2.1.3.1 Fillable syringes
    • TABLE 21 FILLABLE SYRINGES MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.1.3.2 Prefilled syringes
    • TABLE 22 PREFILLED SYRINGES MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.1.4 By usability
    • TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2021-2029 (USD BILLION)
        • 6.2.1.4.1 Reusable injection devices
    • TABLE 24 REUSABLE INJECTION DEVICES MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.1.4.2 Disposable injection devices
    • TABLE 25 DISPOSABLE INJECTION DEVICES MARKET, BY REGION, 2021-2029 (USD BILLION)
    • 6.2.2 SELF-INJECTION DEVICES
    • TABLE 26 SELF-INJECTION DEVICES MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 27 SELF-INJECTION DEVICES MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.2.1 Needle-free injectors
        • 6.2.2.1.1 Instant and painless administration to boost demand
    • TABLE 28 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.1.2 By product
    • TABLE 29 NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2021-2029 (USD BILLION)
          • 6.2.2.1.2.1 Fillable needle-free injectors
    • TABLE 30 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.1.2.2 Prefilled needle-free injectors
    • TABLE 31 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.1.3 By technology
    • TABLE 32 NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD BILLION)
          • 6.2.2.1.3.1 Jet-based needle-free injectors
    • TABLE 33 JET-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.1.3.2 Spring-based needle-free injectors
    • TABLE 34 SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.1.3.3 Laser-based needle-free injectors
    • TABLE 35 LASER-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.1.3.4 Vibration-based needle-free injectors
    • TABLE 36 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.1.4 By usability
    • TABLE 37 NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2021-2029 (USD BILLION)
          • 6.2.2.1.4.1 Reusable needle-free injectors
    • TABLE 38 REUSABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.1.4.2 Disposable needle-free injectors
    • TABLE 39 DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.2.2 Autoinjectors
        • 6.2.2.2.1 Automated dose delivery to enhance patient care
    • TABLE 40 AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.2.2 By product
    • TABLE 41 AUTOINJECTORS MARKET, BY PRODUCT, 2021-2029 (USD BILLION)
          • 6.2.2.2.2.1 Fillable autoinjectors
    • TABLE 42 FILLABLE AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.2.2.2 Prefilled autoinjectors
    • TABLE 43 PREFILLED AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.2.3 By technology
    • TABLE 44 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD BILLION)
          • 6.2.2.2.3.1 Automated autoinjectors
    • TABLE 45 AUTOMATED AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.2.3.2 Manual autoinjectors
    • TABLE 46 MANUAL AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.2.4 By design
    • TABLE 47 AUTOINJECTORS MARKET, BY DESIGN, 2021-2029 (USD BILLION)
          • 6.2.2.2.4.1 Standardized autoinjectors
    • TABLE 48 STANDARDIZED AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.2.4.2 Customized autoinjectors
    • TABLE 49 CUSTOMIZED AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.2.5 By usability
    • TABLE 50 AUTOINJECTORS MARKET, BY USABILITY, 2021-2029 (USD BILLION)
          • 6.2.2.2.5.1 Reusable autoinjectors
    • TABLE 51 REUSABLE AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.2.5.2 Disposable autoinjectors
    • TABLE 52 DISPOSABLE AUTOINJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.2.3 Pen injectors
        • 6.2.2.3.1 Multi-dose devices that can administer dosage subcutaneously
    • TABLE 53 PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
    • TABLE 54 TABLE COMMERCIALLY AVAILABLE PEN INJECTORS
        • 6.2.2.3.2 By product
    • TABLE 55 PEN INJECTORS MARKET, BY PRODUCT, 2021-2029 (USD BILLION)
          • 6.2.2.3.2.1 Single-chambered pen injectors
    • TABLE 56 SINGLE-CHAMBERED PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.3.2.2 Dual-chambered pen injectors
    • TABLE 57 DUAL-CHAMBERED PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.3.3 By design
    • TABLE 58 PEN INJECTORS MARKET, BY DESIGN, 2021-2029 (USD BILLION)
          • 6.2.2.3.3.1 Standard pen injectors
    • TABLE 59 STANDARD PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.3.3.2 Customized pen injectors
    • TABLE 60 CUSTOMIZED PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.2.2.3.4 By usability
    • TABLE 61 PEN INJECTORS MARKET, BY USABILITY, 2021-2029 (USD BILLION)
          • 6.2.2.3.4.1 Reusable pen injectors
    • TABLE 62 REUSABLE PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.2.2.3.4.2 Disposable pen injectors
    • TABLE 63 DISPOSABLE PEN INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.2.4 Wearable injectors
        • 6.2.2.4.1 High efficacy and enhanced safety to drive market
    • TABLE 64 WEARABLE INJECTORS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.2.2.5 Other devices
    • TABLE 65 INJECTABLE DRUG DELIVERY MARKET FOR OTHER DEVICES, BY REGION, 2021-2029 (USD BILLION)
  • 6.3 FORMULATIONS
    • TABLE 66 INJECTABLE DRUG DELIVERY MARKET FOR FORMULATIONS, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 67 INJECTABLE DRUG DELIVERY MARKET FOR FORMULATIONS, BY REGION, 2021-2029 (USD BILLION)
    • 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
    • TABLE 68 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 69 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.3.1.1 Solutions
        • 6.3.1.1.1 High stability and sterility benefits to fuel uptake
    • TABLE 70 SOLUTIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.3.1.2 Reconstituted/lyophilized formulations
        • 6.3.1.2.1 Suitable for parenteral administration
    • TABLE 71 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.3.1.3 Suspensions
        • 6.3.1.3.1 administered using conventional syringes or cartridges
    • TABLE 72 SUSPENSIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.3.1.4 Emulsions
        • 6.3.1.4.1 Thermodynamic dispersions delivered intravenously
    • TABLE 73 EMULSIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
    • 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS
    • TABLE 74 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 75 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.3.2.1 Colloidal dispersions
    • TABLE 76 COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 77 COLLOIDAL DISPERSIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.3.2.1.1 Niosomes
          • 6.3.2.1.1.1 Features include versatility and flexibility
    • TABLE 78 NIOSOMES MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.3.2.1.2 Liposomes
          • 6.3.2.1.2.1 Non-toxic and biocompatible with several indications
    • TABLE 79 LIPOSOMES MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.3.2.1.3 Polymeric/mixed micelles
          • 6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates
    • TABLE 80 POLYMERIC/MIXED MICELLES MARKET, BY REGION, 2021-2029 USD BILLION)
        • 6.3.2.1.4 Nanoparticles
    • TABLE 81 NANOPARTICLES MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 82 NANOPARTICLES MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.3.2.1.4.1 Solid-lipid nanoparticles
  • 6.3.2.1.4.1.1 High uptake in parenteral nutrition
    • TABLE 83 SOLID-LIPID NANOPARTICLES MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.3.2.1.4.2 Nanosuspensions
  • 6.3.2.1.4.2.1 Ability to enhance solubility and permeability of drug formulations
    • TABLE 84 NANOSUSPENSIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
          • 6.3.2.1.4.3 Nanoemulsions
  • 6.3.2.1.4.3.1 Utilized in antibiotic therapy and vaccine delivery
    • TABLE 85 NANOEMULSIONS MARKET, BY REGION, 2021-2029 (USD BILLION)
      • 6.3.2.2 Microparticles
    • TABLE 86 MICROPARTICLES MARKET, BY TYPE, 2021-2029 (USD BILLION)
        • 6.3.2.2.1 Microspheres
          • 6.3.2.2.1.1 Particulate carrier systems with high bioavailability
    • TABLE 87 MICROSPHERES MARKET, BY REGION, 2021-2029 (USD BILLION)
        • 6.3.2.2.2 Microcapsules
          • 6.3.2.2.2.1 Polymeric excipients with biodegradable features
    • TABLE 88 MICROCAPSULES MARKET, BY REGION, 2021-2029 (USD BILLION)
    • 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS
      • 6.3.3.1 Advantages include cost efficiency and low side effects
    • TABLE 89 LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY REGION, 2021-2029 (USD BILLION)

7 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 90 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
  • 7.2 AUTOIMMUNE DISEASES
    • TABLE 91 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2029 (USD BILLION)
    • 7.2.1 RHEUMATOID ARTHRITIS
      • 7.2.1.1 Increased focus on early-stage diagnosis and treatment to propel segment growth
    • TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021-2029 (USD BILLION)
    • 7.2.2 MULTIPLE SCLEROSIS
      • 7.2.2.1 Increasing target patient pool to drive market
    • TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2029 (USD BILLION)
    • 7.2.3 CROHN'S DISEASE
      • 7.2.3.1 Increasing use of liposomes to aid segment growth
    • TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR CROHN'S DISEASE, BY REGION, 2021-2029 (USD BILLION)
    • 7.2.4 PSORIASIS
      • 7.2.4.1 Lifestyle changes and high disease prevalence to support market growth
    • TABLE 96 INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY REGION, 2021-2029 (USD BILLION)
    • 7.2.5 OTHER AUTOIMMUNE DISEASES
    • TABLE 97 INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY REGION, 2021-2029 (USD BILLION)
  • 7.3 HORMONAL DISORDERS
    • TABLE 98 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2021-2029 (USD BILLION)
    • 7.3.1 DIABETES
      • 7.3.1.1 Growing preference for self-injection devices over traditional syringes to augment market growth
    • TABLE 99 INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2021-2029 (USD BILLION)
    • 7.3.2 ANEMIA
      • 7.3.2.1 Increasing occurrence of nutritional deficiency to drive market
    • TABLE 100 INJECTABLE DRUG DELIVERY MARKET FOR ANEMIA, BY REGION, 2021-2029 (USD BILLION)
    • 7.3.3 REPRODUCTIVE HEALTH DISEASES
      • 7.3.3.1 Lack of healthcare facilities and hygiene practices to aid market growth
    • TABLE 101 INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY REGION, 2021-2029 (USD BILLION)
    • 7.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
      • 7.3.4.1 High efficacy and safety of heparin for antithrombotic therapy to drive segment
    • TABLE 102 INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY REGION, 2021-2029 (USD BILLION)
    • 7.3.5 OSTEOPOROSIS
      • 7.3.5.1 Increasing number of women with calcium and vitamin D deficiency to boost segment growth
    • TABLE 103 INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY REGION, 2021-2029 (USD BILLION)
    • 7.3.6 GROWTH HORMONE DEFICIENCY
      • 7.3.6.1 Increased need for daily injections of recombinant human growth hormones to fuel market growth
    • TABLE 104 INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021-2029 (USD BILLION)
  • 7.4 ORPHAN DISEASES
    • 7.4.1 INCREASING NUMBER OF LEGAL AND FINANCIAL INITIATIVES BY GOVERNMENT TO AUGMENT MARKET GROWTH
    • TABLE 105 INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY REGION, 2021-2029 (USD BILLION)
  • 7.5 CANCER
    • 7.5.1 RISING PREVALENCE OF CANCER AND GROWING AVAILABILITY OF THERAPEUTICS TO DRIVE MARKET
    • TABLE 106 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2021-2029 (USD BILLION)
  • 7.6 INFECTIOUS DISEASES
    • 7.6.1 ENVIRONMENTAL CHANGES AND INCREASED MICROBIAL ADAPTATION TO BOOST MARKET GROWTH
    • TABLE 107 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2029 (USD BILLION)
  • 7.7 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 108 INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2029 (USD BILLION)
    • 7.7.1 PAIN MANAGEMENT
      • 7.7.1.1 Increasing number of new drugs for chronic pain management to aid market growth
    • TABLE 109 INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY REGION, 2021-2029 (USD BILLION)
    • 7.7.2 ALLERGIES
      • 7.7.2.1 Increasing prevalence of asthma and eczema to drive market
    • TABLE 110 INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY REGION, 2021-2029 (USD BILLION)
    • 7.7.3 AESTHETIC TREATMENTS
      • 7.7.3.1 Growing popularity of aesthetic procedures to propel segment growth
    • TABLE 111 INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY REGION, 2021-2029 (USD MILLION)
    • 7.7.4 HEPATITIS C
      • 7.7.4.1 Reuse of injectables and inadequate equipment sterilization to drive market
    • TABLE 112 INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY REGION, 2021-2029 (USD BILLION)
    • 7.7.5 HEMOPHILIA
      • 7.7.5.1 Increasing need for preventive treatment plans to propel segment growth
    • TABLE 113 INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY REGION, 2021-2029 (USD MILLION)

8 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING

  • 8.1 INTRODUCTION
    • TABLE 114 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
  • 8.2 AMPOULES
    • 8.2.1 HELPS MAINTAIN STABILITY OF DRUGS, THEREBY ENHANCING EFFICACY
    • TABLE 115 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY REGION, 2021-2029 (USD BILLION)
  • 8.3 VIALS
    • 8.3.1 ABILITY TO STORE DRUG FORMULATIONS FOR EXTENSIVE PERIODS
    • TABLE 116 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY REGION, 2021-2029 (USD BILLION)
  • 8.4 CARTRIDGES
    • 8.4.1 OFFERS HIGHER DOSE ACCURACY AND PATIENT CONVENIENCE
    • TABLE 117 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY REGION, 2021-2029 (USD BILLION)
  • 8.5 BOTTLES
    • 8.5.1 STORAGE OF SOLUTIONS AND EMULSIONS
    • TABLE 118 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY REGION, 2021-2029 (USD BILLION)

9 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

  • 9.1 INTRODUCTION
    • TABLE 119 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
  • 9.2 CURATIVE CARE
    • 9.2.1 ADMINISTRATION OF THERAPEUTIC MEDICATIONS FOR EARLY DISEASE DETECTION TO PROPEL MARKET
    • TABLE 120 INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY REGION, 2021-2029 (USD BILLION)
  • 9.3 IMMUNIZATION
    • 9.3.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
    • TABLE 121 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY REGION, 2021-2029 (USD BILLION)
  • 9.4 OTHER USAGE PATTERNS
    • TABLE 122 INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY REGION, 2021-2029 (USD BILLION)

10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION

  • 10.1 INTRODUCTION
    • TABLE 123 TABLE 1: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
  • 10.2 SKIN-BASED ADMINISTRATION
    • 10.2.1 RAPID & EFFECTIVE METHOD WITH LOW PAIN TO DRIVE MARKET
    • TABLE 124 INJECTABLE DRUG DELIVERY MARKET FOR SKIN-BASED ADMINISTRATION, BY REGION, 2021-2029 (USD BILLION)
  • 10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
    • 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT MARKET GROWTH
    • TABLE 125 INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY REGION, 2021-2029 (USD BILLION)
  • 10.4 ORGAN-BASED ADMINISTRATION
    • 10.4.1 UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST DEMAND
    • TABLE 126 INJECTABLE DRUG DELIVERY MARKET BY ORGAN-BASED ADMINISTRATION, BY REGION, 2021-2029 (USD BILLION)
  • 10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
    • 10.5.1 ADOPTION OF MIS TECHNIQUES TO DRIVE MARKET
    • TABLE 127 INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY REGION, 2021-2029 (USD BILLION)

11 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

  • 11.1 INTRODUCTION
    • TABLE 128 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
  • 11.2 HOSPITALS
    • 11.2.1 HIGH UPTAKE OF ADVANCED DRUG FORMULATIONS TO DRIVE MARKET
    • TABLE 129 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2021-2029 (USD BILLION)
  • 11.3 RETAIL PHARMACY STORES
    • 11.3.1 SALE OF OTC AND PRESCRIPTION DRUGS TO SUPPORT MARKET GROWTH
    • TABLE 130 INJECTABLE DRUG DELIVERY MARKET FOR RETAIL PHARMACY STORES, BY REGION, 2021-2029 (USD BILLION)

12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS

  • 12.1 INTRODUCTION
    • TABLE 131 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
  • 12.2 HOSPITALS AND CLINICS
    • 12.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
    • TABLE 132 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2029 (USD BILLION)
  • 12.3 HOME CARE SETTINGS
    • 12.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
    • TABLE 133 INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021-2029 (USD BILLION)
  • 12.4 OTHER PATIENT CARE SETTINGS
    • TABLE 134 INJECTABLE DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2021-2029 (USD BILLION)

13 INJECTABLE DRUG DELIVERY MARKET, BY REGION

  • 13.1 INTRODUCTION
    • 13.1.1 NORTH AMERICA: RECESSION IMPACT
    • TABLE 135 INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2021-2029 (USD BILLION)
  • 13.2 NORTH AMERICA
    • FIGURE 29 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021-2029 (USD BILLION)
    • TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 141 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 142 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 143 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 144 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.2.1 US
      • 13.2.1.1 US to command largest share in North American injectable drug delivery market during forecast period
    • TABLE 145 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 146 US: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 147 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 148 US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 149 US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 150 US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 151 US: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 152 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 153 US: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.2.2 CANADA
      • 13.2.2.1 Increasing government support and rising incidence of chronic diseases to drive market
    • TABLE 154 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 155 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 156 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 157 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 158 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 159 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 160 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 161 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 162 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
  • 13.3 EUROPE
    • 13.3.1 EUROPE: RECESSION IMPACT
    • TABLE 163 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021-2029 (USD BILLION)
    • TABLE 164 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 165 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 166 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 167 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 168 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 169 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 170 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 171 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 172 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.3.2 GERMANY
      • 13.3.2.1 High healthcare expenditure and increased focus on pharmaceutical R&D to drive market
    • TABLE 173 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 174 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 175 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 176 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 177 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 178 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 179 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 180 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 181 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.3.3 FRANCE
      • 13.3.3.1 Increasing geriatric population and rising incidence of autoimmune diseases to spur market growth
    • TABLE 182 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 183 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 184 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 185 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 186 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 187 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 188 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 189 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 190 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.3.4 UK
      • 13.3.4.1 Growing adoption of generics and increasing collaborations between government and private bodies to aid market growth
    • TABLE 191 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 192 UK: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 193 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 194 UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 195 UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 196 UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 197 UK: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 198 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 199 UK: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.3.5 ITALY
      • 13.3.5.1 Low healthcare expenditure and economic downturn to limit market growth
    • TABLE 200 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 201 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 202 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 203 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 204 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 205 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 206 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 207 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 208 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.3.6 SPAIN
      • 13.3.6.1 Increasing number of mergers and acquisitions to support market growth
    • TABLE 209 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 210 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD MILLION)
    • TABLE 211 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 212 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 213 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 214 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 215 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 216 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 217 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.3.7 REST OF EUROPE
    • TABLE 218 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 219 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 220 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 221 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 222 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 223 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 224 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 225 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 226 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
  • 13.4 ASIA PACIFIC
    • 13.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 30 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
    • TABLE 227 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021-2029 (USD BILLION)
    • TABLE 228 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 229 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 230 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 231 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 232 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 233 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 234 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 235 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 236 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.4.2 CHINA
      • 13.4.2.1 Rising prevalence of chronic diseases to augment market growth
    • TABLE 237 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 238 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 239 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 240 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 241 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 242 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 243 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 244 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 245 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.4.3 JAPAN
      • 13.4.3.1 Growing geriatric population and rising demand for self-injections to drive market
    • TABLE 246 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 247 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 248 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 249 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 250 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 251 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 252 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 253 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 254 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.4.4 INDIA
      • 13.4.4.1 High incidence of cancer and increased adoption of biosimilars to fuel market growth
    • TABLE 255 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 256 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 257 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 258 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 259 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 260 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 261 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • 13.4.5 AUSTRALIA
      • 13.4.5.1 Increase in R&D funding and favorable taxation policies to fuel market growth
    • TABLE 262 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 263 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 264 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 265 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 266 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 267 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 268 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 269 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 270 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.4.6 SOUTH KOREA
      • 13.4.6.1 Increasing focus on aesthetic injectable treatments to drive market
    • TABLE 271 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 272 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 273 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 274 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 275 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 276 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 277 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 278 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 279 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.4.7 REST OF ASIA PACIFIC
    • TABLE 280 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 281 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 282 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 283 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 284 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 285 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 286 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 287 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 288 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
  • 13.5 LATIN AMERICA
    • 13.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 289 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021-2029 (USD BILLION)
    • TABLE 290 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 291 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 292 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 293 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 294 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 295 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 296 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 297 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 298 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.5.2 BRAZIL
      • 13.5.2.1 Increasing obesity and rising incidence of chronic diseases to augment market growth
    • TABLE 299 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 300 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 301 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 302 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 303 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 304 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 305 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 306 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 307 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.5.3 MEXICO
      • 13.5.3.1 Growing medical tourism and increasing focus of government on healthcare to propel market
    • TABLE 308 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 309 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 310 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 311 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 312 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 313 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 314 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 315 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 316 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.5.4 REST OF LATIN AMERICA
    • TABLE 317 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 318 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 319 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 320 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 321 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 322 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 323 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 324 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 325 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 326 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2021-2029 (USD BILLION)
    • TABLE 327 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 328 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 329 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 330 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 331 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 332 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 333 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 334 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 335 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.6.2 GCC COUNTRIES
      • 13.6.2.1 Increasing healthcare expenditure to drive market
    • TABLE 336 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 337 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 338 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 339 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 340 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 341 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 342 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 343 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 344 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)
    • 13.6.3 REST OF MIDDLE EAST & AFRICA
    • TABLE 345 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 346 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021-2029 (USD BILLION)
    • TABLE 347 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021-2029 (USD BILLION)
    • TABLE 348 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021-2029 (USD BILLION)
    • TABLE 349 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021-2029 (USD BILLION)
    • TABLE 350 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021-2029 (USD BILLION)
    • TABLE 351 REST OF MIDDLE EAST AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021-2029 (USD BILLION)
    • TABLE 352 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021-2029 (USD BILLION)
    • TABLE 353 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD BILLION)

14 COMPETITIVE LANDSCAPE

  • 14.1 OVERVIEW
  • 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 31 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 14.3 REVENUE ANALYSIS
    • FIGURE 32 SEGMENTAL REVENUE ANALYSIS FOR KEY PLAYERS, 2020-2023 (USD MILLION)
  • 14.4 MARKET SHARE ANALYSIS
    • FIGURE 33 INJECTABLE DRUG DELIVERY MARKET SHARE ANALYSIS, BY KEY PLAYER (2023)
    • TABLE 354 INJECTABLE DRUG DELIVERY MARKET: DEGREE OF COMPETITION
  • 14.5 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2023
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • FIGURE 34 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
    • 14.5.5 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
    • TABLE 355 FORMULATION PACKAGING: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
    • TABLE 356 THERAPEUTIC APPLICATIONS: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
    • TABLE 357 USAGE PATTERN: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023)
    • TABLE 358 SITE OF ADMINISTRATION: INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS (2023)
    • TABLE 359 REGION FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS (2023)
    • FIGURE 35 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
  • 14.6 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
    • 14.6.1 STARS
    • 14.6.2 EMERGING LEADERS
    • 14.6.3 PERVASIVE PLAYERS
    • 14.6.4 PARTICIPANTS
    • FIGURE 36 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
    • 14.6.5 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
    • TABLE 360 FORMULATION PACKAGING: INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS (2023)
    • TABLE 361 THERAPEUTIC APPLICATIONS: INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS (2023)
    • TABLE 362 USAGE PATTERN: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
    • TABLE 363 SITE OF ADMINISTRATION: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
    • TABLE 364 REGION FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023)
    • FIGURE 37 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
    • 14.6.6 COMPANY BENCHMARKING
    • TABLE 365 INJECTABLE DRUG DELIVERY MANUFACTURERS MARKET
  • 14.7 COMPANY VALUATION AND FINANCIAL METRICS
    • FIGURE 38 EV/EBITDA OF KEY VENDORS
    • FIGURE 39 5-YEAR STOCK BETA OF KEY VENDORS
  • 14.8 PRODUCT/BRAND COMPARISON
    • FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY TYPE (2023)
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 366 INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
    • 14.9.2 DEALS
    • TABLE 367 INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2021- MARCH 2024

15 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
  • 15.1 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
    • 15.1.1 BECTON, DICKINSON AND COMPANY
    • TABLE 368 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
    • FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
    • TABLE 369 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
    • TABLE 370 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS
    • TABLE 371 BECTON, DICKINSON AND COMPANY: DEALS
    • TABLE 372 BECTON, DICKINSON AND COMPANY: EXPANSIONS
    • 15.1.2 PFIZER, INC.
    • TABLE 373 PFIZER, INC.: COMPANY OVERVIEW
    • FIGURE 42 PFIZER, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 374 PFIZER, INC.: PRODUCTS OFFERED
    • TABLE 375 PFIZER, INC.: PRODUCT APPROVALS
    • TABLE 376 PFIZER, INC.: DEALS
    • 15.1.3 JOHNSON & JOHNSON SERVICES, INC.
    • TABLE 377 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
    • FIGURE 43 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)
    • TABLE 378 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
    • TABLE 379 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 380 JOHNSON & JOHNSON SERVICES, INC.: DEALS
    • 15.1.4 SANDOZ GROUP AG
    • TABLE 381 SANDOZ GROUP AG: COMPANY OVERVIEW
    • FIGURE 44 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)
    • TABLE 382 SANDOZ GROUP AG: PRODUCTS OFFERED
    • TABLE 383 SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS
    • TABLE 384 SANDOZ GROUP AG: DEALS
    • 15.1.5 MERCK& CO., INC.
    • TABLE 385 MERCK & CO. INC.: COMPANY OVERVIEW
    • FIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2022)
    • TABLE 386 MERCK & CO., INC.: PRODUCTS OFFERED
    • TABLE 387 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 388 MERCK & CO., INC.: DEALS
    • 15.1.6 GLAXOSMITHKLINE PLC
    • TABLE 389 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
    • FIGURE 46 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022)
    • TABLE 390 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
    • TABLE 391 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS
    • TABLE 392 GLAXOSMITHKLINE PLC: DEALS
    • TABLE 393 GLAXOSMITHKLINE PLC: EXPANSIONS
    • 15.1.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 394 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
    • FIGURE 47 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 395 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
    • TABLE 396 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS
    • TABLE 397 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS
    • 15.1.8 ELI LILLY AND COMPANY
    • TABLE 398 ELI LILLY AND COMPANY: COMPANY OVERVIEW
    • FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
    • TABLE 399 ELI LILLY AND COMPANY: PRODUCTS OFFERED
    • TABLE 400 ELI LILLY AND COMPANY: PRODUCTS LAUNCHES & APPROVALS
    • TABLE 401 ELI LILLY AND COMPANY: DEALS
    • TABLE 402 ELI LILLY AND COMPANY: EXPANSIONS
    • 15.1.9 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 403 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
    • TABLE 404 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
    • TABLE 405 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS
    • TABLE 406 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS
    • 15.1.10 BAXTER INTERNATIONAL, INC.
    • TABLE 407 BAXTER INTERNATIONAL, INC.: COMPANY OVERVIEW
    • FIGURE 49 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 408 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED
    • TABLE 409 BAXTER INTERNATIONAL, INC.: PRODUCT APPROVALS
    • 15.1.11 GERRESHEIMER AG
    • TABLE 410 GERRESHEIMER AG: COMPANY OVERVIEW
    • FIGURE 50 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)
    • TABLE 411 GERRESHEIMER AG: PRODUCTS OFFERED
    • TABLE 412 GERRESHEIMER AG: PRODUCT LAUNCHES
    • TABLE 413 GERRESHMEIMER AG: DEALS
    • 15.1.12 SCHOTT PHARMA
    • TABLE 414 SCHOTT PHARMA: COMPANY OVERVIEW
    • FIGURE 51 SCHOTT AG: COMPANY SNAPSHOT (2022)
    • TABLE 415 SCHOTT PHARMA: PRODUCTS OFFERED
    • TABLE 416 EXPANSIONS
  • 15.2 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
    • 15.2.1 TERUMO CORPORATION
    • TABLE 417 TERUMO CORPORATION: COMPANY OVERVIEW
    • FIGURE 52 TERUMO CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 418 TERUMO CORPORATION: PRODUCTS OFFERED
    • TABLE 419 PRODUCT LAUNCHES & APPROVALS
    • 15.2.2 ANTARES PHARMA, INC.
    • TABLE 420 ANTARES PHARMA, INC.: COMPANY OVERVIEW
    • 15.2.3 B. BRAUN MELSUNGEN AG
    • TABLE 421 B. BRAUN MELSUNGEN AG: COMPANY OVERVIEW
    • 15.2.4 SMITHS MEDICAL
    • TABLE 422 SMITHS MEDICAL: COMPANY OVERVIEW
    • 15.2.5 FRESENIUS KABI AG
    • TABLE 423 FRESENIUS KABI AG: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 RELATED REPORTS
  • 16.4 AUTHOR DETAILS